FDA - Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies
August 25, 2022
FDA - Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies.
This final guidance is intended to help applicants (or “you”) design and conduct tobacco product perception and intention (TPPI) studies that may be submitted as part of a modified risk tobacco product application (MRTPA), a premarket tobacco product application (PMTA), or a substantial equivalence report (SE Report). TPPI studies are studies that can be used to assess, among other things, individuals’ perceptions of tobacco products, understanding of tobacco product information (e.g., labeling, modified risk information), and intentions to use tobacco products. It is possible for a TPPI study to also include an actual use component (e.g., an actual product utilized in a simulated use setting or a real environment of use); however, a discussion of actual use research is beyond the scope of this final guidance. This final guidance addresses the following scientific issues for applicants to consider as they design and conduct TPPI studies to support tobacco product applications:
Developing TPPI study aims and hypotheses
Designing quantitative and qualitative TPPI studies
Selecting and adapting measures of TPPI study constructs
Recently Released Final Rule Extends FDA’s Authority to ALL Tobacco Products
On May 5, 2016, the FDA published a final rule, extending the Agency’s authority to all tobacco products, including, but not limited to, e-cigarettes, cigars, and hookah and pipe tobacco. This rule,...
FDA Updates Requirements Regarding Health Document Submissions for Tobacco Products
On Friday, September 9th, FDA announced the availability of a revised draft guidance, entitled “Health Document Submission Requirements for Tobacco Products.” The document was initially published in...